NCT07016152View on ClinicalTrials.gov

An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

November 5, 2026

Study Completion Date

April 10, 2027

Conditions
Klebsiella Pneumoniae InfectionVaccine
Interventions
BIOLOGICAL

Glyconjugate Klebsiella pneumoniae bivalent vaccine

CHO-V08 is a glycoconjugate bivalent vaccine in sterile suspension.

Trial Locations (1)

100025

RECRUITING

National Taiwan University Hospital- Clinical Trial Center, Taipei

Sponsors

Lead Sponsor

Cho Pharma Inc.
All Listed Sponsors
lead

Cho Pharma Inc.

INDUSTRY

NCT07016152 - An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults | Biotech Hunter | Biotech Hunter